Biologics

#Abiologics #Artificial intelligence (AI) #Biologics #Generative AI #Synthetic biology

Abiologics launches with a new class of supranatural medicines

Abiologics, a Flagship Pioneering company, has launched to develop a new class of supranatural and programmable medicines called Synteins. Synteins are computationally-generated and synthesised with novel building blocks, potentially providing treatments across a wide range of diseases. Flagship has initially committed $50 million to advance the company’s platform and develop… Read More

#Business & Investment #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Seed fund
#Biologics #Seed funding #Start-ups #University of Dundee

Dundee spin-out raises £4m to advance VLPs

Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More

#News #Start-up Zone

#Antibodies #Artificial intelligence (AI) #Biologics #Investment #Seed funding #Start-ups

AI drug discovery company Xaira launches with $1b investment

Xaira Therapeutics, a joint incubation by ARCH Venture Partners and Foresite Labs, has launched with more than $1 billion of committed capital from lead investors. Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological… Read More

#News #Start-up Zone #Trending News

Laboratory research
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

Next week: Accelerate development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News

Two scientists working in a research laboratory
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

Accelerate the development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence (AI) both… Read More

#Exclusive Content

Medical researchers
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

How to accelerate the development of advanced biotherapeutics

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron… Read More

Webinar date:
Brought to you by Revvity
#News

Women working in a research laboratory
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC #Webinar

The benefits of higher throughput bioanalytical methods

Join DDW for this free event, ‘Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics’, which is supported by Revvity. It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will presented by Ron Morena,… Read More

Webinar date:
Brought to you by Revvity
#News

Women working in a research laboratory
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC

Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics

Successful development of advanced biotherapeutics relies on extensive characterisation and tight quality control. Characterising binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches have… Read More

Webinar date:
Brought to you by Revvity
#Webinars

Monoclonal antibodies
#Antibody discovery workflow #Antibody-based therapeutics #App note #Biologics #Monoclonal antibodies

App Note: How Merck creates developability profiles for mAbs

Download this new Application Note to discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach… Read More

#News

#Antibody discovery workflow #Antibody-based therapeutics #Biologics #Monoclonal antibodies

Biologics developability: How Merck creates developability profiles for their mAbs

In this Application Note, discover how the Protein Sciences group at Merck & Co. builds developability profiles for their monoclonal antibody variants. Get an in-depth explanation of the experiments they set up to obtain parameters that help them decide which candidates have the best potential to reach the market, and how they… Read More

#Resources

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

New DDW Highlights podcast: 19 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week our news highlights focus on skin conditions, with positive updates on hidradenitis… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

This week in drug discovery (12-16 February) 

News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. The top stories: Dual-action treatment… Read More

#News